3rd Quarter - Report — OMNICARE, INC. for OMNICARE INC (2014)

Firm

OMNICARE, INC.

Client

OMNICARE INC

Income

—

Expenses

$70,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Medicare Part D reimbursement; Reimbursement for prescription drugs for hospice patients; E-Prescribing in long-term care; Medicaid FFS drug reimbursement; Medicare innovative health care and delivery models; Post-acute care payment policy reform; Medicare Part D network access issues; Safe-harbor and anti-kickback policy

Lobbyist	Covered position, as disclosed
JAMES FLOOD	—
ELIZABETH TERRY	—

Contacted: Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS); Drug Enforcement Administration (DEA); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE

Pharmacy PHA

Drug Enforcement Administration proposed rule on disposal of controlled substances in long term care facilities; Reclassification of hydrocodone-containing prescription drugs from Schedule III to Schedule II drugs; Controlled substances policy; Biosimilars policy

Lobbyist	Covered position, as disclosed
JAMES FLOOD	—
ELIZABETH TERRY	—

Contacted: HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); SENATE; Drug Enforcement Administration (DEA); Centers For Medicare and Medicaid Services (CMS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.